Efficacy

SYMBYAX shows clinically significant improvement of bipolar depression symptoms

Improvement in MADRS Total Score for the SYMBYAX group was statistically greater than placebo at week 8.¹

Statistical analysis is based on pooled data from two independent studies. SYMBYAX was superior to both placebo and olanzapine monotherapy in both studies at 8-week endpoint. MADRS is Montgomery-Asberg Depression Rating Scale, consisting of 10 items. Olanzapine monotherapy did not separate from placebo in both studies

Olanzapine is not approved for the treatment of bipolar depression.

1. Data on file, Lilly Research Laboratories.
† Treatment arm numbers as of week 1.
‡ LOCF is Last Observation Carried Forward.

SYMBYAX offers clinically significant remission rates in bipolar depression.

SYMBYAX showed remission rates as high as 69% in pooled studies.¹

Clinically, response is defined as an improvement of symptoms, whereas remission is a return to baseline level of functioning.

In this study, remission is defined as MADRS Total Score <12 at any time over the 8-week study period and completion of at least 4 weeks.

Olanzapine is not approved for the treatment of bipolar depression.

1. Data on file, Lilly Research Laboratories.

NOTE: To view or print PDF files, you must have Adobe® Reader®. Click here to download the free reader.